Tag: MGC018
Risvutatug Rezetecan Demonstrates Overall Survival Benefit Over Topotecan in Relapsed Small...
Interim results from the pivotal Phase 3 ARTEMIS-008 trial (NCT06498479) show that risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, significantly reduced the risk of death...
B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid...
B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid Tumors
ASCO 2020 – Promising Development in the Advancement of Antibody-drug Conjugates
With an increasing number of antibody-drug conjugates (ADC) being approved and commercially available for the treatment of patients with cancer and hematological malignancies, the...
Rapid Advances in the Development of Novel ADCs Targeting B7-H3 and...
With five antibody-drug conjugates (ADC) having received approval from the United States Food and Drug Administration (FDA) and other regulators around the world and...
MacroGenics and Synthon Biopharmaceuticals Sign Agreement
MacroGenics and Synthon Biopharmaceuticals have signed an agreement to license and collaborate in he development of MGC018, an antibody-drug conjugate or ADC directed against...
